Predict your next investment

XtalPi company logo
Corporation
INTERNET | Internet Software & Services / Scientific, Engineering
xtalpi.com

See what CB Insights has to offer

Founded Year

2014

Stage

Series D | Alive

Total Raised

$783.81M

Valuation

$0000 

Last Raised

$400M | 3 mos ago

About XtalPi

XtalPi is a cloud-based technology company that solves drug polymorphism by providing accurate computational crystal structure prediction for small-molecule drugs.

XtalPi Headquarter Location

20th Floor, East Block, Times Technology Building, 7028 Shennan Avenue, Futian District

Shenzhen, Guangdong,

China

+86-755-21005829

Latest XtalPi News

Big Pharma companies join hands with Amazon on new Israel-based AI incubator

Oct 13, 2021

Nicole DeFeudis Editor What do Mer­ck, Pfiz­er, As­traZeneca and Te­va have in com­mon with Ama­zon? As of Wednes­day, they’re all join­ing forces with the Is­rael Biotech Fund to launch a new in­cu­ba­tor for star­tups walk­ing the line be­tween AI and drug de­vel­op­ment — and they’re gear­ing up to make some big in­vest­ments. AION Labs plans to seed be­tween four and six new biotech com­pa­nies per year, start­ing in ear­ly 2022, CEO Mati Gill told End­points News. The funds should sup­port two to four years of run­way for each start­up. “We have com­peti­tors that are work­ing to­geth­er…be­cause the chal­lenge of har­ness­ing AI and com­pu­ta­tion­al ca­pa­bil­i­ties for phar­ma is so im­mense and it re­al­ly hasn’t been tapped in­to,” Gill said in an in­ter­view. AION’s roots trace back to Te­va where Gill was most re­cent­ly a se­nior ex­ec­u­tive in charge of out­reach. The phar­ma com­pa­ny was ini­tial­ly look­ing to strength­en its ties with Is­rael’s ro­bust tech com­mu­ni­ty when it came up with the idea for the col­lab­o­ra­tion. Then in De­cem­ber, they won more than $9 mil­lion in an Is­raeli gov­ern­ment ten­der to get start­ed. How will it work? AION is copy­ing its mod­el from Bio­Med X, a part­ner and bio­med­ical in­cu­ba­tor based in Hei­del­berg, Ger­many. Each year, AION’s phar­ma part­ners will se­lect at least four of the biggest chal­lenges faced by drug­mak­ers in the AI space and is­sue calls for so­lu­tions. Five to 10 fi­nal­ists will be of­fered a chance to spend a week in Is­rael at a boot­camp, where they’ll de­vel­op their pro­pos­als. In the end, the win­ners will be of­fered seed fund­ing to form a com­pa­ny around their ideas. Jim Weather­all Gill ex­pects to an­nounce the first round of ap­pli­ca­tions lat­er this month. “Da­ta, an­a­lyt­ics and AI are al­ready start­ing to trans­form the way we dis­cov­er and de­vel­op new med­i­cines and I be­lieve we are on­ly at the tip of the ice­berg in terms of its promise,” Jim Weather­all, As­traZeneca’s VP of da­ta sci­ence and AI R&D, said in a state­ment. This isn’t the first in­stance of Big Phar­ma dip­ping its toes in the AI space. Back in May, Bris­tol My­ers Squibb ex­pand­ed a Cel­gene-era deal with AI out­fit Ex­sci­en­tia. And be­fore that, back in Feb­ru­ary, As­traZeneca said it added the first tar­get gen­er­at­ed by AI to its port­fo­lio, com­ing out of a col­lab­o­ra­tion with the Lon­don-based com­pa­ny, Benev­o­len­tAI. Sev­er­al oth­er biotechs have cropped up with big promis­es to speed up the drug de­vel­op­ment process us­ing ma­chine learn­ing and oth­er AI-fo­cused mod­els, in­clud­ing In­sil­i­co, Deep Ge­nomics, Re­cur­sion, XtalPi and oth­ers. AUTHOR Zachary Brennan Senior Editor CBER director Peter Marks praised Janet Woodcock’s work as acting FDA commissioner, and while noting that Biden needs to nominate someone to fill the role permanently by Nov. 16, he said he has “no idea” when that actually might occur. “Dr. Woodcock has been at the agency for over three decades and she, during that time, has proven herself to be a remarkably capable manager,” Marks said at the Alliance for Regenerative Medicine’s meeting Tuesday. “And she’s been managing as if she’s commissioner, unlike some previous acting [commissioners] who are afraid to actually do things. She doesn’t appear to be afraid to do things. I have not felt any different now from when we had a commissioner in place,” he added. Premium subscription required Kyle Blankenship Managing Editor Paul Stoffels, the scientific lead behind J&J’s refresh of its hallowed Janssen unit and the creation of the company’s single-shot Covid-19 vaccine, will retire at the end of the year, joining CEO Alex Gorsky on the way out the door and setting up a new era of leadership at the industry’s biggest drugmaker. As the man most responsible for J&J’s hard pivot back into R&D over the course of the past decade, Stoffels was responsible for propping up an oncology R&D unit that ranks among the largest in the industry as well as driving J&J’s efforts across a broad range of therapeutic areas. Keep reading Endpoints with a free subscription Unlock this story instantly and join 119,600+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Jason Mast Editor When Mark Denison awoke this month to learn that another one of the drugs from his lab had proven effective against Covid-19, two thoughts rushed through his mind. “I was so excited to hear that it had this potential,” he said. “And then I thought: Our resistance work is more important than ever.” Denison, 66, is arguably the scientist most responsible for molnupiravir, the pill Merck announced last week cut the risk of hospitalization or death in newly diagnosed Covid-19 patients by 50%. It came to his Vanderbilt lab alongside another molecule known as 3a — or, as it was later rechristened, remdesivir —  in the years after the 2012 MERS outbreak, as Denison worked to identify drugs that could be deployed in the event of another deadly coronavirus spillover. Keep reading Endpoints with a free subscription Unlock this story instantly and join 119,600+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Kyle Blankenship Managing Editor As Eli Lilly works to consolidate its internal and Loxo teams into an oncology powerhouse, the drug giant is putting high hopes on CDK 4/6 inhibitor Verzenio to help drive the portfolio into the future. Now, the drug has scored a paradigm-altering win in early breast cancer — but will a controversial companion diagnostic hamstring Lilly’s market plans? The FDA on Wednesday approved CDK 4/6 inhibitor Verzenio in combination with physician’s-choice endocrine therapy to cut the risk of relapse in patients with high-risk HR-positive, HER2-negative breast cancer, Lilly said in a release. Keep reading Endpoints with a free subscription Unlock this story instantly and join 119,600+ biopharma pros reading Endpoints daily — and it's free. SIGN UP Zachary Brennan Senior Editor While both Pfizer/BioNTech and Moderna are looking to administer boosters for their Covid-19 vaccines six months after the initial two-dose series, J&J — which has vaccinated about 15 million Americans so far with its one-shot vaccine — is taking a more unique approach with boosters. According to briefing documents released ahead of Friday’s FDA adcomm on the booster dose, J&J is calling for its boosters to be administered anywhere from two months to six months following the initial shot, depending on the strength of the immune responses. Read More October 13, 2021 08:00 AM EDTUpdated 10:01 AM Paul Schloesser Editorial Intern Madhu Natarajan can trace his fascination with the idea of taking B cells and turning them into protein factories back 20 years, when he had his own lab at UT Southwestern. So when Natarajan, now the rare disease development head for Takeda, sat down for a meet-up with execs from Seattle-based Immusoft at the last in-person JP Morgan conference, they went straight into a brainstorming session. “That B cells can take up residence and do what they do for a long time,” says Natarajan, pumping out proteins and “leveraging it into a therapeutic context,” hits his sweet spot for discovery deals. And he was deeply impressed by what he heard. Keep reading Endpoints with a free subscription Unlock this story instantly and join 119,600+ biopharma pros reading Endpoints daily — and it's free. SIGN UP

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing XtalPi

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned XtalPi in 4 CB Insights research briefs, most recently on Jul 16, 2021.

Expert Collections containing XtalPi

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

XtalPi is included in 6 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

865 items

A

Artificial Intelligence ( AI ) in Healthcare

826 items

These healthcare startups are using AI to discover new drugs, remotely monitor patients, securely transfer patient data, and more.

G

Google In Healthcare

61 items

The healthcare companies and initiatives that Google has invested in or is a part of

S

Sequoia Capital China Investments 2018-2019

149 items

A

Artificial Intelligence

7,895 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

H

Healthcare Companies Backed By China's Big Tech

110 items

Baidu, Alibaba, Tencent, and Ping An have collectively invested in 106 unique companies in healthcare.

XtalPi Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

XtalPi Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.